Rieke Alten Selected Research

Abatacept (Orencia)

8/2022	Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study.
4/2020	Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study.
11/2019	Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries.
5/2019	Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
1/2019	Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
9/2018	Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective.
1/2018	Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
12/2017	Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.
10/2017	The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.
1/2017	Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rieke Alten Research Topics

Disease

68	Rheumatoid Arthritis 08/2022 - 06/2002
13	Rheumatic Diseases (Rheumatism) 06/2022 - 06/2013
8	Fatigue 12/2021 - 01/2009
6	Pain (Aches) 01/2022 - 01/2016
6	Ankylosing Spondylitis 12/2021 - 01/2005
6	Infections 11/2021 - 03/2007
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 06/2022 - 01/2022
3	COVID-19 06/2022 - 01/2022
3	Chronic Disease (Chronic Diseases) 10/2020 - 07/2011
3	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 06/2015 - 06/2011
2	Joint Diseases (Joint Disease) 06/2022 - 10/2017
2	Arthritis (Polyarthritis) 06/2022 - 06/2015
2	Axial Spondyloarthritis 12/2021 - 10/2014
2	Necrosis 01/2020 - 05/2016
2	Psoriatic Arthritis 06/2019 - 06/2015
2	Injection Site Reaction 01/2018 - 08/2014
2	Inflammation (Inflammations) 09/2016 - 01/2008
2	Neoplasms (Cancer) 01/2015 - 08/2014
1	Synovitis 06/2022
1	Cross Infection (Nosocomial Infection) 01/2022
1	Osteoporosis 12/2020
1	Bone Resorption 01/2019
1	Pneumonia (Pneumonitis) 01/2018
1	Opportunistic Infections (Opportunistic Infection) 01/2018
1	Myocardial Infarction 01/2018
1	Hypersensitivity (Allergy) 01/2018
1	Gout 12/2017
1	Overweight 10/2017
1	Human Influenza (Influenza) 01/2016
1	Psoriasis (Pustulosis Palmaris et Plantaris) 06/2015
1	Crohn Disease (Crohn's Disease) 06/2015
1	Ulcerative Colitis 06/2015
1	Non-Radiographic Axial Spondyloarthritis 10/2014
1	Rare Diseases (Rare Disease) 06/2013
1	Castleman Disease (Castleman's Disease) 06/2011

Drug/Important Bio-Agent (IBA)

19	Abatacept (Orencia)FDA Link 08/2022 - 06/2002
19	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 11/2003
17	Biological ProductsIBA 12/2021 - 01/2009
13	Infliximab (Remicade)FDA Link 06/2022 - 01/2005
12	Antirheumatic Agents (DMARD)IBA 12/2021 - 06/2011
10	Adalimumab (Humira)FDA Link 01/2021 - 05/2013
9	Biosimilar PharmaceuticalsIBA 01/2021 - 06/2015
7	GlucocorticoidsIBA 12/2020 - 01/2008
7	Prednisone (Sone)FDA LinkGeneric 07/2015 - 01/2008
6	AutoantibodiesIBA 06/2022 - 09/2016
5	Tumor Necrosis Factor InhibitorsIBA 12/2021 - 06/2011
5	Rheumatoid FactorIBA 01/2019 - 01/2009
5	tocilizumab (atlizumab)FDA Link 01/2017 - 03/2008
4	Pharmaceutical PreparationsIBA 06/2022 - 01/2018
4	ametantrone (HAQ)IBA 10/2020 - 01/2014
3	PF-06410293IBA 01/2021 - 01/2018
3	FKB327IBA 11/2020 - 12/2019
3	GP1111IBA 04/2020 - 01/2018
3	AntibodiesIBA 01/2019 - 03/2007
3	Interleukin-6 (Interleukin 6)IBA 01/2019 - 03/2008
3	Proteins (Proteins, Gene)FDA Link 01/2019 - 11/2003
3	Monoclonal AntibodiesIBA 01/2019 - 01/2008
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2014 - 03/2007
2	CT-P13IBA 01/2021 - 01/2021
2	Etanercept (Enbrel)FDA Link 01/2021 - 10/2014
2	3-benzoyl dopamine (MBDA)IBA 01/2019 - 09/2016
2	C-Reactive ProteinIBA 01/2018 - 10/2017
2	Uric Acid (Urate)IBA 12/2017 - 01/2016
2	AntigensIBA 01/2016 - 11/2003
2	CytokinesIBA 07/2015 - 01/2008
2	canakinumab FDA Link 07/2011 - 01/2008
2	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 06/2011 - 03/2008
1	baricitinibIBA 01/2022
1	Rituximab (Mabthera)FDA Link 11/2021
1	Leflunomide (Arava)FDA LinkGeneric 11/2021
1	GLPG0634IBA 01/2021
1	Janus Kinase InhibitorsIBA 10/2020
1	tofacitinibIBA 10/2020
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	LigandsIBA 01/2019
1	BI 655064IBA 01/2019
1	Immunoglobulin A (IgA)IBA 01/2019
1	Immunoglobulin M (IgM)IBA 01/2019
1	Immunoglobulins (Immunoglobulin)IBA 01/2019
1	Matrix Metalloproteinase 3 (Stromelysin 1)IBA 01/2019
1	Xanthine OxidaseIBA 12/2017
1	lesinuradIBA 12/2017
1	Certolizumab Pegol FDA Link 06/2017
1	Anti-Citrullinated Protein AntibodiesIBA 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	EnzymesIBA 01/2017
1	Transaminases (Aminotransferases)IBA 01/2017
1	antineoplaston A10 (A 10)IBA 01/2016
1	23-valent pneumococcal capsular polysaccharide vaccineIBA 01/2016
1	VaccinesIBA 01/2016
1	Guanosine Diphosphate (GDP)IBA 11/2014
1	N 30IBA 10/2014
1	Sulfasalazine (Azulfidine)FDA LinkGeneric 10/2014
1	InterleukinsIBA 07/2011

Therapy/Procedure

22	Therapeutics 06/2022 - 11/2003
3	Chronotherapy 02/2012 - 07/2010
1	Activities of Daily Living (ADL) 01/2021
1	Immunomodulation 06/2019
1	Biological Therapy 01/2019
1	Contraindications 12/2017